Every day, our field-proven, AI-powered diagnostic solutions help pathologists ensure better cancer care for patients around the world


Created by pathologists for pathologists


Delivering real-world clinical impact


The worldwide leader in live clinical rollouts


Platform of choice for the world’s leading physicians, health systems and diagnostic solution providers

Ibex Raises $55 Million in Series C Funding

The funding round is to Drive Global Adoption of AI for Cancer Diagnosis and was led by 83NORTH and included Sienna Venture Capital and existing investors Octopus Ventures, aMoon Fund, Planven Entrepreneur Ventures and Dell Technologies Capital.

Read More

The Ibex Difference

  • AI-powered solutions detect cancer and more than a hundred other diagnostic features in multiple tissue types

  • Clinically-proven accuracy, enhanced efficiency and improved user experience
  • Developed from rich datasets extracted from over 10 million slides from multiple pathology institutes
  • Multiple AI algorithms trained by teams of expert pathologists using deep learning technologies
Trusted AI

Why Ibex


Accurate, timely, personalized cancer diagnosis for every patient


Higher quality,
more targeted,
high-impact care


Enhanced physician confidence and patient safety


Faster diagnosis, better user experience and lower pathology workloads


Optimized workflows improve productivity across the cancer pathway

Customers & Partners

The role of AI in pathology and how it impacts cancer care

Prof. Stuart Schnitt from Brigham and Women's Hospital talks about Galen Breast and how its accuracy and broad detection capabilities transform pathologists' work

Watch Now

Experience the future of pathology

Contact Us

    By providing my details I agree to the IBEX Terms and conditions and Privacy policy. I also agree to receive emails from IBEX and I understand that I may opt out of IBEX subscriptions at any time.